FI940681A0 - Menetelmä ja koostumuksia, jotka liittyvät Moraxella catarrhalisin käyttökelpoisiin antigeeneihin - Google Patents

Menetelmä ja koostumuksia, jotka liittyvät Moraxella catarrhalisin käyttökelpoisiin antigeeneihin

Info

Publication number
FI940681A0
FI940681A0 FI940681A FI940681A FI940681A0 FI 940681 A0 FI940681 A0 FI 940681A0 FI 940681 A FI940681 A FI 940681A FI 940681 A FI940681 A FI 940681A FI 940681 A0 FI940681 A0 FI 940681A0
Authority
FI
Finland
Prior art keywords
moraxella catarrhalis
omps
proteins
methods
variants
Prior art date
Application number
FI940681A
Other languages
English (en)
Swedish (sv)
Other versions
FI106844B (fi
FI940681A (fi
Inventor
Eric J Hansen
Merja Helminen
Isobel Maciver
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Publication of FI940681A0 publication Critical patent/FI940681A0/fi
Publication of FI940681A publication Critical patent/FI940681A/fi
Application granted granted Critical
Publication of FI106844B publication Critical patent/FI106844B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C07K14/212—Moraxellaceae, e.g. Acinetobacter, Moraxella, Oligella, Psychrobacter
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1217—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
FI940681A 1991-08-15 1994-02-14 Menetelmä Moraxella catarrhalisin antigeeneihin liittyvien koostumusten ja vasta-aineiden valmistamiseksi sekä DNA-segmentti, yhdistelmävektori ja yhdistelmäisäntäsolu FI106844B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US74559191 1991-08-15
US07/745,591 US5552146A (en) 1991-08-15 1991-08-15 Methods and compositions relating to useful antigens of Moraxella catarrhalis
PCT/US1992/006869 WO1993003761A1 (en) 1991-08-15 1992-08-14 METHODS AND COMPOSITIONS RELATING TO USEFUL ANTIGENS OF $i(MORAXELLA CATARRHALIS)
US9206869 1992-08-14

Publications (3)

Publication Number Publication Date
FI940681A0 true FI940681A0 (fi) 1994-02-14
FI940681A FI940681A (fi) 1994-04-07
FI106844B FI106844B (fi) 2001-04-30

Family

ID=24997358

Family Applications (1)

Application Number Title Priority Date Filing Date
FI940681A FI106844B (fi) 1991-08-15 1994-02-14 Menetelmä Moraxella catarrhalisin antigeeneihin liittyvien koostumusten ja vasta-aineiden valmistamiseksi sekä DNA-segmentti, yhdistelmävektori ja yhdistelmäisäntäsolu

Country Status (14)

Country Link
US (3) US5552146A (fi)
EP (1) EP0612250B1 (fi)
JP (1) JP3499868B2 (fi)
KR (1) KR100271888B1 (fi)
AT (1) ATE140627T1 (fi)
AU (1) AU666329B2 (fi)
CA (1) CA2115565C (fi)
DE (1) DE69212495T2 (fi)
DK (1) DK0612250T3 (fi)
ES (1) ES2092696T3 (fi)
FI (1) FI106844B (fi)
GR (1) GR3021423T3 (fi)
NO (2) NO308413B1 (fi)
WO (1) WO1993003761A1 (fi)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2693654B1 (fr) * 1992-07-20 1994-08-26 Oreal Médicament, notamment immunomodulateur, contenant des enveloppes ou fractions d'enveloppes de bactéries filamenteuses non photosynthétiques et non fructifiantes, et sa préparation.
DE69423383T2 (de) * 1993-05-13 2000-08-24 American Cyanamid Co Herstellung und Verwendungen von LOS-verminderten Aussenmembran-Proteinen von Gram-negativen Kokken
US5712118A (en) * 1993-09-29 1998-01-27 Research Foundation Of State University Of New York Vaccine for branhamella catarrhalis
US5607846A (en) * 1994-05-17 1997-03-04 Research Foundation Of State University Of New York Vaccine for moraxella catarrhalis
US6121427A (en) * 1994-10-24 2000-09-19 Connaught Laboratories Limited Major outer membrane protein CD of branhamella
US6335018B1 (en) * 1995-05-01 2002-01-01 Aventis Pasteur Limited High molecular weight major outer membrane protein of moraxella
US6440425B1 (en) * 1995-05-01 2002-08-27 Aventis Pasteur Limited High molecular weight major outer membrane protein of moraxella
US6290970B1 (en) 1995-10-11 2001-09-18 Aventis Pasteur Limited Transferrin receptor protein of Moraxella
KR100500000B1 (ko) * 1996-05-03 2005-12-12 안텍스 바이오로직스 인코퍼레이션 모락셀라카타르할리스외측막단백질-16폴리펩티드,이의유전자서열및이의용도
US7341727B1 (en) * 1996-05-03 2008-03-11 Emergent Product Development Gaithersburg Inc. M. catarrhalis outer membrane protein-106 polypeptide, methods of eliciting an immune response comprising same
US6004562A (en) * 1996-08-16 1999-12-21 The Research Foundation Of The State University Of New York Outer membrane protein B1 of Moraxella catarrhalis
US6558677B2 (en) * 1996-10-15 2003-05-06 Wendell D. Zollinger Vaccine against gram negative bacteria
AU746442B2 (en) 1996-12-20 2002-05-02 Board Of Regents, The University Of Texas System UspA1 and UspA2 antigens of Moraxella catarrhalis
GB9810084D0 (en) 1998-05-11 1998-07-08 Cortecs Uk Ltd Proteins
EP1078065A2 (en) * 1998-05-12 2001-02-28 SMITHKLINE BEECHAM BIOLOGICALS s.a. Compounds from moraxella catarrhalis
GB9810285D0 (en) 1998-05-13 1998-07-15 Smithkline Beecham Biolog Novel compounds
GB9812440D0 (en) * 1998-06-09 1998-08-05 Smithkline Beecham Biolog Novel compounds
MY125387A (en) 1999-03-19 2006-07-31 Smithkline Beecham Biologicals S A Vaccine
GB9914945D0 (en) * 1999-06-25 1999-08-25 Smithkline Beecham Biolog Novel compounds
GB9921691D0 (en) 1999-09-14 1999-11-17 Smithkline Beecham Sa Novel compounds
GB0022742D0 (en) 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
GB0103171D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
SI2255826T1 (sl) 2002-08-02 2016-07-29 Glaxosmithkline Biologicals S.A. Neisserijski vakcinski sestavki, ki obsegajo kombinacijo antigenov
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
US7709001B2 (en) 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
CA2604363C (en) 2005-04-08 2015-06-16 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
NO346529B1 (no) 2005-12-22 2022-09-26 Glaxosmithkline Biologicals Sa Bruk av et immunogenpreparat for småbarn, omfattende 22F sakkaridkonjugat
MY150105A (en) 2006-01-17 2013-11-29 Forsgren Arne A novel surface exposed haemophilus influenzae protein (protein e; pe)
CN101883583B (zh) 2007-06-26 2017-05-17 葛兰素史密丝克莱恩生物有限公司 含有肺炎链球菌荚膜多糖缀合物的疫苗
AU2009262893B2 (en) 2008-05-30 2015-05-21 The U.S.A., as represented by The Secretary of the Army, on behalf of Walter Reed Army Institute Of Research Meningococcal multivalent native outer membrane vesicle vaccine, methods of making and use thereof
GB201003924D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Immunogenic composition
GB201003922D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
JP2013521770A (ja) 2010-03-10 2013-06-13 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン組成物
GB201103836D0 (en) 2011-03-07 2011-04-20 Glaxosmithkline Biolog Sa Conjugation process
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
IE87414B1 (en) 2017-05-30 2023-07-19 Glaxosmithkline Biologicals Sa Novel methods for manufacturing an adjuvant
EP3717001A1 (en) 2017-12-01 2020-10-07 GlaxoSmithKline Biologicals S.A. Saponin purification
CA3107077A1 (en) 2018-08-07 2020-02-13 Glaxosmithkline Biologicals Sa Processes and vaccines
WO2020109365A1 (en) 2018-11-29 2020-06-04 Glaxosmithkline Biologicals Sa Methods for manufacturing an adjuvant
CN114080393A (zh) 2019-06-05 2022-02-22 葛兰素史克生物有限公司 皂苷纯化
GB202205833D0 (en) 2022-04-21 2022-06-08 Glaxosmithkline Biologicals Sa Bacteriophage
WO2024017827A1 (en) 2022-07-19 2024-01-25 Glaxosmithkline Biologicals Sa Continuous process for vaccine production

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5030556A (en) * 1989-03-30 1991-07-09 Danielle Beaulieu Species-specific DNNA probe for the detection of Branhamella catarrhalis

Also Published As

Publication number Publication date
AU666329B2 (en) 1996-02-08
FI106844B (fi) 2001-04-30
DE69212495D1 (de) 1996-08-29
EP0612250A1 (en) 1994-08-31
DK0612250T3 (da) 1996-11-25
NO20002413L (no) 2000-05-09
CA2115565C (en) 2007-08-07
US5552146A (en) 1996-09-03
DE69212495T2 (de) 1997-03-06
ES2092696T3 (es) 1996-12-01
AU2487892A (en) 1993-03-16
NO940502L (no) 1994-03-28
US5599693A (en) 1997-02-04
JPH07501210A (ja) 1995-02-09
US5759813A (en) 1998-06-02
CA2115565A1 (en) 1993-03-04
KR100271888B1 (ko) 2000-11-15
GR3021423T3 (en) 1997-01-31
NO940502D0 (no) 1994-02-14
WO1993003761A1 (en) 1993-03-04
EP0612250B1 (en) 1996-07-24
ATE140627T1 (de) 1996-08-15
NO308413B1 (no) 2000-09-11
JP3499868B2 (ja) 2004-02-23
FI940681A (fi) 1994-04-07
NO20002413D0 (no) 2000-05-09

Similar Documents

Publication Publication Date Title
FI940681A (fi) Menetelmä ja koostumuksia, jotka liittyvät Moraxella catarrhalisin käyttökelpoisiin antigeeneihin
MX9708438A (es) Proteina principal de la membrana externa de moraxella, de alto peso molecular.
DE69229476T2 (de) Ospa proteine von borrelia burgdorferi untergruppen, dafür kodierende gene sowie impfstoffe
ATE497004T1 (de) Moraxella catarrhalis antigene uspa1 und uspa2
NO976119L (no) OMP26-antigen fra Haemophilus influenzae
DE69331901T2 (de) Impfstoff auf urease-basis gegen helicobacter infektionen
EP0090581A3 (en) Small peptides with the specificity of foot and mouth disease viral antigens
ATE105334T1 (de) Schimaerische glykoproteine enthaltende immunogenische abschnitte von menschlichem parainfluenzavirus typ 3.
DE69419966D1 (de) Impstoff gegen Streptococcus suis-Infektion
FI924457A (fi) Kompositioner och behandlingsfoerfarande foer lunginflammation i djur
DK482788D0 (da) Vacciner mod og diagnostiske bestemmelser af haemophilus influenzae
YU12991A (sh) Rekombinantne vakcine protiv kokcidioze-5-7 eimeria površinski antigen
ATA171686A (de) Verfahren zur herstellung von gegen pseudomonas aeruginosa infektionen wirksamen praeparationen
FR2736064B1 (fr) Epitopes protecteurs de l'adenyl cyclase-hemolysine(ac-hty). leur application au traitement ou a la prevention des infections par bordetella
ATE154244T1 (de) Induzierung eines schutzes gegen virale infektionen
ATE138269T1 (de) Zweiphasensystem zur herstellung und präsentation von fremdantigenen in hybriden lebendimpfstoffen
FI902814A0 (fi) Proteiner, vaccin och nukleinsyror.
ATE103817T1 (de) Gegen pseudomonas aeruginosa-infektionen wirksame praeparationen sowie immunglobulin-g-haeltige, gegen bakterium pseudomonas aeruginosa wirksame praeparationen.
WO1996034884A3 (en) Synthetic peptides of m. gallisepticum, antibodies thereto, their preparation and use